Clearpoint Neuro Stock Today
| CLPT Stock | USD 14.03 0.35 2.56% |
PerformanceWeakest
| Odds Of DistressLow
|
Clearpoint Neuro is selling for under 14.03 as of the 3rd of January 2026; that is 2.56 percent increase since the beginning of the trading day. The stock's last reported lowest price was 13.5. Clearpoint Neuro has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 5th of October 2025 and ending today, the 3rd of January 2026. Click here to learn more.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 29.75 M outstanding shares of which 2.92 M shares are currently shorted by private and institutional investors with about 4.68 trading days to cover. More on Clearpoint Neuro
Moving together with Clearpoint Stock
Moving against Clearpoint Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Clearpoint Stock Highlights
| CEO President | Joseph Burnett |
| Old Name | Collplant Holdings Ltd |
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) |
Clearpoint Neuro (CLPT) is traded on NASDAQ Exchange in USA and employs 115 people. Clearpoint Neuro is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 417.37 M. Clearpoint Neuro conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 29.75 M outstanding shares of which 2.92 M shares are currently shorted by private and institutional investors with about 4.68 trading days to cover.
Clearpoint Neuro currently holds about 45.14 M in cash with (8.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Check Clearpoint Neuro Probability Of Bankruptcy
Ownership AllocationClearpoint Neuro holds a total of 29.75 Million outstanding shares. 30% of Clearpoint Neuro outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Clearpoint Ownership Details
Clearpoint Neuro Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Clearpoint Neuro market risk premium is the additional return an investor will receive from holding Clearpoint Neuro long position in a well-diversified portfolio.
| Mean Deviation | 3.7 | |||
| Standard Deviation | 5.23 | |||
| Variance | 27.39 | |||
| Risk Adjusted Performance | (0.11) |
Clearpoint Stock Against Markets
Clearpoint Neuro Corporate Management
| Mazin Sabra | Chief Officer | Profile | |
| Danilo DAlessandro | Chief Officer | Profile | |
| Ellisa JD | General Secretary | Profile | |
| Ellisa Cholapranee | General Secretary | Profile | |
| Jeremy Stigall | Executive Delivery | Profile | |
| Jacqueline Keller | Vice Marketing | Profile |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.